Navigation Links
Oetzi's last days
Date:1/28/2009

Another chapter in a murder case over 5000 years old. New investigations by an LMU research team working together with a Bolzano colleague reconstructed the chronology of the injuries that Oetzi, the glacier man preserved as a frozen mummy, received in his last days. It turns out, for example, that he did in fact only survive the arrow wound in his back for a very short time a few minutes to a number of hours, but no more and also definitely received a blow to the back with a blunt object only shortly before his death. In contrast, the cut wound on his hand is some days older. "We are now able to make the first assertions as to the age and chronology of the injuries," reports Professor Andreas Nerlich, who led the study. "It is now clear that Oetzi endured at least two injuring events in his last days, which may imply two separate attacks. Although the ice mummy has already been studied at great length, there are still new results to be gleaned. The crime surrounding Oetzi is as thrilling as ever!"

It is the oldest ice mummy ever found. Oetzi, the man from the Neolithic Age, is giving science critical information about life more than 5000 years ago, not least from his equipment. His copper axe, for example, reveals that metalworking was already much more advanced in that era than was previously assumed. Yet Oetzi's body, too, gives us many details as to his diet, state of health and not least to his murder.

"Some time ago, we detected a deep cut wound on Oetzi's hand that he must have survived for at least a couple of days," says Nerlich, head of the Institute of Pathology at Municipal Hospital Munich-Bogenhausen and member of the Medical Faculty of LMU. "Another team at about the same time found an arrow tip in Oetzi's left armpit. The shaft of the arrow was missing, but there is an entry wound on the back." It is probable, in that case, that the man died of internal bleeding because the arrow hit a main artery. What was unclear, however
'/>"/>

Contact: Luise Dirscherl
dirscherl@lmu.de
Ludwig-Maximilians-Universitt Mnchen
Source:Eurekalert

Page: 1 2


Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...SNewswire/ -- The American Association of Homes an...te for passing Sen. Michael Bennet,s (D-Colo.) ame...anteed benefits, and strengthens Medicare by keepi...ver tsunami of retiring baby boomers fast approach...tion currently before Congress to address Medicare...
(Date:12/3/2009)...reas, but each patient will be different, experts ...) -- A class of drugs still taken by millions of ...igher risk of dying and heart failure than the new...lfonylureas, long a mainstay of diabetes treatment... oral anti-diabetes drugs, but doctors said the fi...
(Date:12/3/2009)...ing of diabetes, cardiovascular disease, researche...ews) -- Pregnant women who develop gestational glu...isk for metabolic syndrome three months after they...ucose intolerance is less severe than gestational ... factors (including high blood pressure, obesity a...
(Date:12/3/2009)...f screening test, researcher says, , ,...h points to the possibility of a genetic link betw...high blood pressure who had a gene variant that re...to be twice as likely as those without the variant.... , The finding may lead to a way to identify p...
(Date:12/3/2009)... -- Chiltern International Limited (Chiltern), a g...ng clinical development and staffing services in E...appointment of Dr. Sharon Moore as Executive Vic... Dr. Moore is based at Chiltern,s Bristol, Tenness...h 15 years of industry experience. Prior to joinin...
Breaking Medicine News(10 mins):Health News:Diabetes Drugs Go Head-to-Head in Study 2Health News:Diabetes Drugs Go Head-to-Head in Study 3Health News:Blood Sugar Intolerance May Predict Postpartum Ills 2Health News:Vitamin D May Be Tied to Heart Disease Via Genes 2Health News:Chiltern Names Dr. Sharon Moore as Executive VP, Global Quality & Medical Affairs 2
...cation of modulated radiotherapy in the treatment ...y means of other conventional therapies. The techn...ost adapted to the tumoral volume and risk areas, ...total dose equivalent to conventional ones. In thi...
...it comes to injury-related deaths, the gap between...ording to a study by researchers at the Johns Hopk...ound that between 1999 and 2005 injury-related dea... Injury Prevention . , "Between the years of 199...
...rnational Living Ultimate Event, held recently in ...most from the U.S. and Canada - who are, looking t...ing for better access to quality health car... their,homework so they don,t make mistakes. That ...
...NIO, June 16 BME (BioMedical Enterprises,Inc.), a...in orthopaedic,shape memory implant technology, to...) (BOSS), a nitinol implant designed for internal ...OSS nitinol,staple changes shape when heated above...
...ship Provides the Medical Device Industry with Bes...utions, PRINCETON JUNCTION, N.J., June 16 R-Squa...nd solutions, announced a,multi-year partnership w... including manufacturers of medical,devices and di...
...CLE #1 FOR IMMEDIATE RELEASE , Coffee,s aroma ki...ural and Food Chemistry , Drink coffee to send a..., warm aroma? An international group of scientists...ats, they found that coffee aroma orchestrates the...
Other Medicine News:Health News:Modulated radiotherapy can cut treatment time for cancer of the rectum without increasing toxicity 2Health News:Racial disparities reduced in injury related mortality 2Health News:International Living Ultimate Event Attracts Nearly 300 Attendees Who Explore the Growing Trend of Retiring Overseas 2Health News:International Living Ultimate Event Attracts Nearly 300 Attendees Who Explore the Growing Trend of Retiring Overseas 3Health News:BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitinol Implant 2Health News:R-Squared and MDMA Announce Partnership 2Health News:American Chemical Society's Weekly PressPac: June 11, 2008 2Health News:American Chemical Society's Weekly PressPac: June 11, 2008 3Health News:American Chemical Society's Weekly PressPac: June 11, 2008 4Health News:American Chemical Society's Weekly PressPac: June 11, 2008 5Health News:American Chemical Society's Weekly PressPac: June 11, 2008 6Health News:American Chemical Society's Weekly PressPac: June 11, 2008 7Health News:American Chemical Society's Weekly PressPac: June 11, 2008 8
(Date:12/3/2009)... , KALAMAZOO, Mich., Dec. 3 /PRNewswire-Firs...nced today that its Board of Directors has authori...f its common stock. The manner, timing and amount...y,s management based on their evaluation of market...l be subject to regulatory considerations. Purcha...
(Date:12/3/2009)... , BEDFORD, Mass., Dec. 3 Mi...mplant systems, today announced it has been named ...rum. ,, The company was selected for pioneeri...ted, responsive implants designed to bridge the ga...CHIPS, technologies have broad applicability, from...
(Date:12/3/2009)... , MAPLE GROVE, Minn., Dec. 3 /PRNewswir...ced the next phase of its strategic plan for centr...nded release topiramate), an internally developed ...being developed with Upsher-Smith,s proprietary fo...inical trial in early 2010 for the adjunctive trea...
Breaking Medicine Technology:Stryker Announces $750 Million Share Repurchase Program and Declares a $0.15 Per Share Quarterly Dividend 2MicroCHIPS Named 2010 Technology Pioneer by World Economic Forum 2Upsher-Smith Announces Milestone in Development of CNS Strategy 2Photos 3A 2010 All New Kia Soul Awarded 2009 Top Safety Pick by Insurance Institute for Highway Safety 54439 1Photos 3A 2010 All New Kia Soul Awarded 2009 Top Safety Pick by Insurance Institute for Highway Safety 54439 2Photos 3A 2010 All New Kia Soul Awarded 2009 Top Safety Pick by Insurance Institute for Highway Safety 54439 3AVMA Unveils Improved Online Press Room to Help Journalists 54435 1AVMA Unveils Improved Online Press Room to Help Journalists 54435 2AVMA Unveils Improved Online Press Room to Help Journalists 54435 3Sun Pharmaceutical to File HSR Application for Taro Tender Offer 54431 1Sun Pharmaceutical to File HSR Application for Taro Tender Offer 54431 2Sun Pharmaceutical to File HSR Application for Taro Tender Offer 54431 3
... Jan. 10 Celltrion, Inc., a Korean,biopharmaceuti...act,manufacturing, and CSL Limited, Australia,s le...he signing of an agreement for the development,and...ibody therapy for the,treatment of acute myeloid l... are currently being conducted by CSL in Australia...
...NTREAL, Jan. 9 Pharmion,Corporation (Nasdaq: PHR...,the enrollment of the first patient in a Phase 2 ...the Companies, isotype-selective histone,deacetyla...tion with,Vidaza(R) (azacitidine for injection), P... relapsed or refractory Hodgkin lymphoma (HL) or,n...
Other Medicine Technology:Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody 2Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 2Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 3Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 4Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 5Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 6Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 7
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
Medicine Products: